Progressive renal insufficiency related to ALK inhibitor, alectinib

Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oxf Med Case Reports
Main Authors: Nagai, Kojiro, Ono, Hiroyuki, Matsuura, Motokazu, Hann, Michael, Ueda, Sayo, Yoshimoto, Sakiya, Tamaki, Masanori, Murakami, Taichi, Abe, Hideharu, Ishikura, Hisashi, Doi, Toshio
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915949/
https://ncbi.nlm.nih.gov/pubmed/29713488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omy009
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares